SG11201701803XA - Stabilized adrenomedullin derivatives and use thereof - Google Patents

Stabilized adrenomedullin derivatives and use thereof

Info

Publication number
SG11201701803XA
SG11201701803XA SG11201701803XA SG11201701803XA SG11201701803XA SG 11201701803X A SG11201701803X A SG 11201701803XA SG 11201701803X A SG11201701803X A SG 11201701803XA SG 11201701803X A SG11201701803X A SG 11201701803XA SG 11201701803X A SG11201701803X A SG 11201701803XA
Authority
SG
Singapore
Prior art keywords
stabilized
adrenomedullin derivatives
adrenomedullin
derivatives
stabilized adrenomedullin
Prior art date
Application number
SG11201701803XA
Inventor
Donald Bierer
Ingo Flamme
Johannes Köbberling
Bernd Riedl
Annette Beck-Sickinger
Ria Schoenauer
Jan-Patrick Fischer
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of SG11201701803XA publication Critical patent/SG11201701803XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
SG11201701803XA 2014-09-26 2015-09-24 Stabilized adrenomedullin derivatives and use thereof SG11201701803XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14186572 2014-09-26
PCT/EP2015/071941 WO2016046301A1 (en) 2014-09-26 2015-09-24 Stabilized adrenomedullin derivatives and use thereof

Publications (1)

Publication Number Publication Date
SG11201701803XA true SG11201701803XA (en) 2017-04-27

Family

ID=51610047

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201701803XA SG11201701803XA (en) 2014-09-26 2015-09-24 Stabilized adrenomedullin derivatives and use thereof

Country Status (24)

Country Link
US (1) US20180022780A1 (en)
EP (1) EP3197481A1 (en)
JP (1) JP2018500272A (en)
KR (1) KR20170062490A (en)
CN (1) CN107001440A (en)
AP (1) AP2017009826A0 (en)
AU (1) AU2015323769A1 (en)
CA (1) CA2962486A1 (en)
CO (1) CO2017002813A2 (en)
CR (1) CR20170110A (en)
CU (1) CU20170038A7 (en)
DO (1) DOP2017000085A (en)
EA (1) EA201790699A1 (en)
EC (1) ECSP17018513A (en)
IL (1) IL250927A0 (en)
MA (1) MA40524A (en)
MX (1) MX2017003897A (en)
NI (1) NI201700036A (en)
PE (1) PE20170702A1 (en)
PH (1) PH12017500563A1 (en)
SG (1) SG11201701803XA (en)
TN (1) TN2017000109A1 (en)
WO (1) WO2016046301A1 (en)
ZA (1) ZA201702901B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110678550B (en) * 2017-03-29 2023-11-14 国立大学法人宫崎大学 Long-acting adrenomedullin derivatives
NL2020518B1 (en) * 2018-03-02 2019-09-12 Mimetas B V Device and method for performing electrical measurements
CN114174326A (en) * 2019-06-18 2022-03-11 拜耳公司 Long-term stable adrenomedullin analogues and uses thereof
EP4126062A1 (en) * 2020-04-03 2023-02-08 Bayer Aktiengesellschaft Liquid pharmaceutical formulations polyethylene glycol-based prodrugs of adrenomedullin and use
WO2022177018A1 (en) * 2021-02-22 2022-08-25 国立大学法人宮崎大学 Method for producing long-acting adrenomedullin derivative

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (en) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド Modifications of or for denatured antibodies
US4812590A (en) 1987-06-25 1989-03-14 Merck & Co., Inc. Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
JP2774769B2 (en) * 1993-04-26 1998-07-09 賢治 寒川 Adrenomedullin
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JPH11171896A (en) * 1995-09-19 1999-06-29 Kirin Brewery Co Ltd New peptide compound and its pharmaceutical composition
JP2001506967A (en) 1996-08-02 2001-05-29 ブリストル―マイヤーズ・スクイブ・カンパニー Methods for suppressing immunoglobulin-induced toxicity as a result of the use of immunoglobulins in therapy and in vivo diagnosis
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1124961B9 (en) * 1998-10-23 2010-07-21 Kirin-Amgen Inc. Thrombopoietic compounds
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
EP1141024B1 (en) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc Albumin fusion proteins
US6962972B2 (en) 2000-05-16 2005-11-08 Lipoxen Technologies Limited Derivatization of proteins
US20030033624A1 (en) * 2000-07-06 2003-02-13 Allen Keith D. Transgenic mice containing adrenomedullin receptor gene disruptions
PT1315750E (en) * 2000-08-30 2007-05-31 Hoffmann La Roche Cyclic peptides having melanocortin-4 receptor agonist activity
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
PT1355919E (en) 2000-12-12 2011-03-02 Medimmune Llc Molecules with extended half-lives, compositions and uses thereof
US6888319B2 (en) 2001-03-01 2005-05-03 Palomar Medical Technologies, Inc. Flashlamp drive circuit
JP4336771B2 (en) 2001-03-09 2009-09-30 モルフォシス アーゲー Serum albumin binding moiety
DE10112825A1 (en) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylation of active ingredients in aqueous solution
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
KR101271635B1 (en) 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 Albumin fusion proteins
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003209446B2 (en) 2002-03-01 2008-09-25 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
JP4459810B2 (en) 2002-08-14 2010-04-28 マクロジェニクス，インコーポレーテッド FcγRIIB specific antibody and method of use thereof
US20050271615A1 (en) 2002-08-30 2005-12-08 Doron Shabat Self-immolative dendrimers releasing many active moieties upon a single activating event
EP2364996B1 (en) 2002-09-27 2016-11-09 Xencor Inc. Optimized FC variants and methods for their generation
DE60334141D1 (en) 2002-10-15 2010-10-21 Facet Biotech Corp CHANGE OF FcRn BINDING SAFFINITIES OR SERUM HALF TIMES OF ANTIBODIES BY MUTAGENESIS
GB2395337B (en) 2002-11-14 2005-12-28 Gary Michael Wilson Warning Unit
WO2004043493A1 (en) 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
JP2006524039A (en) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド Identification and production of antibody containing mutant Fc region and use thereof
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
KR101113726B1 (en) 2003-08-12 2012-02-27 리폭센 테크놀로지즈 리미티드 Sialic acid derivatives for protein derivatisation and conjugation
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
UA86605C2 (en) 2004-01-12 2009-05-12 Аплайд Молекьюлер Иволюшн, Инк. Antibody comprising a variant fc region
HUE045882T2 (en) 2004-03-23 2020-01-28 Ascendis Pharma Gmbh Polymeric prodrug with a self-immolative linker
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005116065A1 (en) 2004-05-24 2005-12-08 Institut De Cardiologie De Montréal Labelled adrenomedullin derivatives and their use for imaging and therapy
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
CN103351434B (en) 2004-07-15 2015-09-30 赞科股份有限公司 The Fc variant optimized
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
US7973495B2 (en) 2006-03-13 2011-07-05 Koninklijke Philips Electronics N.V. Adaptive control apparatus and method for a solid state lighting system
WO2008138141A1 (en) 2007-05-11 2008-11-20 Institut De Cardiologie De Montréal Labelled adrenomedullin derivatives and their use for imaging and therapy.
PT2173890E (en) 2007-06-21 2011-05-06 Tech Universit T M Nchen Biological active proteins having increased in vivo and/or vitro stability
ES2354488T3 (en) * 2008-04-18 2011-03-15 F. Hoffmann-La Roche Ag ALFA-N-METHYLATION OF AMINO ACIDS.
CN102076331B (en) 2008-06-26 2013-12-18 普罗林科斯有限责任公司 Prodrugs and drug-macromolecule conjugates having controlled drug release rates
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
NZ628987A (en) 2009-02-03 2015-11-27 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
NZ596787A (en) 2009-06-08 2014-03-28 Amunix Operating Inc Growth hormone polypeptides and methods of making and using same
WO2010144508A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
WO2011028228A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
AU2012240144B2 (en) * 2011-04-07 2017-05-25 The Board Of Trustees Of The Leland Stanford Junior University Long-acting peptide analogs
AU2012331279A1 (en) 2011-11-03 2014-05-08 Bayer Intellectual Property Gmbh Tyrosine based linkers for the releasable connection of peptides
JOP20190001B1 (en) 2011-11-03 2022-03-14 Bayer Pharma AG Polyethylene glycol based prodrug of Adrenomedullin and use thereof

Also Published As

Publication number Publication date
IL250927A0 (en) 2017-04-30
MX2017003897A (en) 2017-06-28
AP2017009826A0 (en) 2017-03-31
DOP2017000085A (en) 2017-04-30
CN107001440A (en) 2017-08-01
CR20170110A (en) 2017-05-08
KR20170062490A (en) 2017-06-07
MA40524A (en) 2021-03-17
CA2962486A1 (en) 2016-03-31
ECSP17018513A (en) 2017-05-31
WO2016046301A1 (en) 2016-03-31
CO2017002813A2 (en) 2017-06-30
EP3197481A1 (en) 2017-08-02
PE20170702A1 (en) 2017-06-24
US20180022780A1 (en) 2018-01-25
PH12017500563A1 (en) 2017-08-30
AU2015323769A1 (en) 2017-04-13
TN2017000109A1 (en) 2018-07-04
JP2018500272A (en) 2018-01-11
NI201700036A (en) 2017-06-16
ZA201702901B (en) 2019-06-26
CU20170038A7 (en) 2017-10-05
EA201790699A1 (en) 2017-10-31

Similar Documents

Publication Publication Date Title
IL249186B (en) Anti-cd20 glycoantibodies and uses thereof
HK1225383A1 (en) Diazepane derivatives and uses thereof
HK1244000B (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
IL252216B (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
HK1231471A1 (en) 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof 6-- 6--2-
FI3215147T3 (en) Neuro-attenuating norketamine compounds and methods
ZA201704227B (en) Drawers and components for drawers
EP3154972A4 (en) Azamophinan derivatives and use thereof
IL247148A0 (en) Pyrazolone compounds and uses thereof
ZA201702901B (en) Stabilized adrenomedullin derivatives and use thereof
ZA201703398B (en) Pharmaceutical composition and methods
HK1243077A1 (en) Piperidinylpyrazolopyrimidinones and their use
HK1243342A1 (en) Compounds and methods
SG11201605915WA (en) Furo-3-carboxamide derivatives and methods of use
HK1232211A1 (en) Dipicolylamine derivatives and their pharmaceutical uses
ZA201701492B (en) Pyrazolothiazole compound and medicine
PL3022215T3 (en) Stabilized form of tetrofosmin and its use
GB201408091D0 (en) Methods and uses
PL3229772T3 (en) 6-aryl-9-glycosylpurines and use thereof
GB201404728D0 (en) Disc-over incorporating disc-heads and disc-earning
GB201414103D0 (en) Solid products and their use
GB201416086D0 (en) Methods and uses
GB201416073D0 (en) Methods and uses
GB201404301D0 (en) Compounds and combinations